Today: 30 June 2026
Browse Category

HOSE:MWG 28 February 2026 - 1 March 2026

Vietnam stocks week ahead: Ho Chi Minh VN-Index faces a settlement test after T+2 glitch

Vietnam stocks week ahead: Ho Chi Minh VN-Index faces a settlement test after T+2 glitch

Ho Chi Minh City, March 1, 2026, 16:19 ICT — The session has ended. The Ho Chi Minh Stock Exchange starts the week facing renewed back-office headaches after the securities depository reported a delay in allocating certain securities set for settlement. The holdup followed scheduled IT maintenance performed by the KRX contractor, according to the VSD.
1 March 2026
······
Vietnam stocks: Ho Chi Minh Stock Exchange VN-Index ends February up as settlement snag puts March in focus

Vietnam stocks: Ho Chi Minh Stock Exchange VN-Index ends February up as settlement snag puts March in focus

Ho Chi Minh City, Feb 28, 2026, 15:56 ICT — The market wrapped up for the day. VN-Index managed a gain of 0.69 points on Friday, closing at 1,880.33. The index hovered near 1,900 through a turbulent week, with fresh flows aimed at fertiliser and oil-and-gas stocks, according to Nhi Nguyen at Shinhan Securities. Nguyen described the action as “a technical shake-out” around resistance. Turnover reached 33.4 trillion dong, and foreign investors swung to a net purchase of roughly 190 billion dong, picking up names like FPT, Gemadept, and Mobile World.
28 February 2026
····

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Go toTop